Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on April 24, 2026, by Jaguar Health, Inc., a Delaware corporation headquartered in San Francisco, California. The filing addresses critical corporate governance actions taken to maintain the company's listing on The Nasdaq Stock Market and the implementation of a reverse stock split approved by shareholders.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on corporate actions regarding stock listing compliance and capital structure adjustments.
Material Changes and Corporate Actions
- Nasdaq Listing Status: The Nasdaq Hearings Panel granted the Company a request to continue its listing, subject to a strict condition. The Company must demonstrate compliance with the Bid Price Rule (Rule 5550(a)(2)) by achieving a closing bid price of at least $1.00 per share for 10 consecutive business days on or before May 15, 2026.
- Reverse Stock Split: Shareholders approved a reverse stock split at a ratio of 1-for-35. This action became effective at 12:01 am Eastern Time on April 30, 2026. Every 35 pre-split shares were reclassified into one post-split share.
- Impact on Securities: The split proportionally adjusts the number of shares issuable upon exercise of options and warrants, while increasing their exercise prices. No fractional shares were issued; cash payments were made in lieu of fractional shares.
- Trading Details: Trading resumed on a split-adjusted basis on April 30, 2026, under the new CUSIP number 47010C862.
Outlook, Risks, and Management Commentary
Management stated it is diligently working to satisfy the Nasdaq Panel's decision but noted there is no assurance of success. Failure to meet the May 15, 2026, deadline will result in delisting from Nasdaq. The Panel retains jurisdiction over the Company until September 1, 2026, and may reconsider the exception if significant events occur that question the Company's ability to comply. The filing includes standard forward-looking statement disclaimers regarding the uncertainty of achieving the required bid price.
Investor Verification Checklist
- Verify the current closing bid price of JAGX stock to assess progress toward the $1.00 threshold required by May 15, 2026.
- Confirm the effective date of the 1-for-35 reverse stock split (April 30, 2026) and the new CUSIP number (47010C862) for trading purposes.
- Review the Company's 2025 Annual Report (Form 10-K) for detailed financial condition and risk factors not included in this 8-K.
- Monitor for any subsequent 8-K filings regarding the Company's compliance status with the Nasdaq Bid Price Rule before the May 15 deadline.